

## TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007

**Leuven (Belgium) – May 17, 2013** – TiGenix NV (Euronext Brussels: TIG) publishes today transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

TiGenix received, and has published on its website, the following transparency notifications:

1. Termination of agreement to act in concert: Joint notification by the following persons acting in concert who concluded an agreement to hold, acquire or dispose of voting securities:
  - a. Koninklijke DSM N.V. (with address at Het Overloon 1, 6411 TE Heerlen, the Netherlands) / Limburg Ventures B.V. (with address at Boschstraat 76, 6211 AX Maastricht, the Netherlands),
  - b. the Dutch State (with address at Bezuidenhoutseweg 20 2594 AV Den Haag, the Netherlands) / N.V. Industriebank LIOF (with address at Boschstraat 76, 6211 AX Maastricht, the Netherlands),
  - c. Stichting De Weijerhorst / Particon B.V. (both with address at Bellefroidlunet 30F, 6221 KN Maastricht, the Netherlands), and
  - d. the Flemish Region (with address at Martelaarsplein 7, 1000 Brussels, Belgium) / LRM NV (with address at Kempischesteeweg 555, 3500 Hasselt, Belgium).

NV Industriebank LIOF, Particon BV, Limburg Ventures BV and LRM NV entered into an investment agreement with Tigenix NV on June 19, 2009. This agreement provided for a lock-up with respect to the new shares issued on June 26, 2009 in the framework of said agreement. The lock-up expired gradually and had completely expired on June 30, 2010. This constituted the end of the agreement to act in concert.

At the time of entering into the investment agreement, the above-mentioned persons together held more than 3% of the denominator at that time (30,868,668 shares).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: DSM Nederland BV is the controlling shareholder of Limburg Ventures BV. Koninklijke DSM N.V. is the controlling shareholder of DSM Nederland BV, and the ultimate controlling shareholders of Limburg Ventures BV. NV Industriebank LIOF is shareholder of Limburg Ventures BV. The Dutch State is the (ultimate) controlling shareholder of NV Industriebank LIOF. De Stichting De Weijerhorst is the (ultimate) controlling shareholder of Particon BV. The Flemish Region is the (ultimate) controlling shareholder of LRM NV.

# TiGENIX

2. Passive crossing below the 3% threshold: Notification by the related companies LRM NV (controlling person) / Mijnen NV (both with address at Kempischesteenweg 555, 3500 Hasselt, Belgium), following the passive crossing below the 3% threshold by Mijnen NV on December 27, 2012, after which the participations of these companies were as follows (compared to the denominator of 100,288,586 shares):
- Mijnen NV: 3,000,000 shares (2.99%),
  - LRM NV: 200,000 shares (0.20%),
  - Total: 3,200,000 shares (3.19%).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Mijnen NV is controlled by LRM NV. LRM NV is controlled by the Flemish Region.

3. Passive crossing below the 5% threshold: Notification by the company Ysios Capital Partners S.G.E.C.R. (with address at Calle Baldiri Reixach 10-12, 08028 Barcelona, Spain), who notifies alone, following the passive crossing below the 5% threshold on December 27, 2012, after which the Company held 4.75% of the shares (or: 4,760,342 shares compared to the denominator of 100,288,586 shares).

Ysios Capital Partners S.G.E.C.R. is the management company of Ysios Biofund I FCR (a collective investment undertaking within the meaning of Article 9, §2 of the Royal Decree of February 14, 2008) and exercises the voting rights attached to the shares owned by this fund at its own discretion.

Ysios Capital Partners S.G.E.C.R. is not controlled.

For further details regarding these notifications, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>.

## **For more information:**

Eduardo Bravo  
Chief Executive Officer  
[eduardo.bravo@tigenix.com](mailto:eduardo.bravo@tigenix.com)

Claudia D'Augusta  
Chief Financial Officer  
[claudia.daugusta@tigenix.com](mailto:claudia.daugusta@tigenix.com)

Hans Herklots  
[hans.herklots@tigenix.com](mailto:hans.herklots@tigenix.com)  
+32 16 39 60 97

## **About TiGenix**

*TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed cell therapy product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit [www.tigenix.com](http://www.tigenix.com).*